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Ontogeny of angiotensin II type 2 (AT2) receptor mRNA in the rat. To
study the distribution of the recently cloned angiotensin II type 2 (AT2)
receptor in the rat fetus, a double stranded eDNA was generated by a new
and recently described methodology requiring no cloning procedure. The
eDNA obtained after reverse transcription (RT) and polymerasc chain
reaction (PCR) amplification corresponded to 500 base pairs of the gene
coding sequence, and included the SP6 and T7 promoters at the 5' and 3'
end, respectively. 35S-labeled cRNA sense and antisenae probes were
synthesized by in vitro transcription and used for in situ hybridization.
From 13 to 19 days of gestation the AT2 receptor mRNA expression
evolved and extended from a series of paired spots located para-axially,
which were not identifiable at this level of observation, to a distribution in
various mescnchymcs (perichondrium, subepidermal layers), muscle cells
(tongue, diaphragm, stomach), and classical target organs for Aug II
(adrenal gland, kidney, aorta). During the first days after birth, the AT2
receptor mRNA decreased and remained detectable only in the adrenal
gland and kidney. The distribution of the AT2 receptor mRNA appeared
strikingly different from that of the AT1A receptor, which was studied in
parallel for comparison.
Angiotensin II (Ang II) is most commonly known as a hor-
monal factor regulating water and salt homeostasis and vasocon-
striction with the kidney, adrenal gland and vascular smooth
muscles as primary targets, and hence participates in the control
of blood pressure. However, a growing body of evidence shows a
role of this peptide as a growth factor in vitro and possibly in vivo
[1, 2]. Whatever the role of Ang II, the current consensus is that
it acts via plasma membrane receptors coupled to intracellular
signaling systems. This mechanism ensures that a single message
can produce various effects in different target cells according to
their intrinsic properties and content of Ang II receptor types.
Ang II binds to at least two pharmacologically distinct types of
receptors, type 1 (AT1) and type 2 (AT2). Both these receptors
have similar affinities for Ang II, but they have strikingly different
properties towards peptidic and non-peptidic antagonists : AT1
has a high affinity for losartan (DuP 753), AT2 for PD123177 and
CGP 42112 [1, 2].
Functionally, the AT1 receptor appears to mediate most or all
of the known effects of Ang II. The cloning of the AT1 receptor
cDNA has revealed the existence of two closely related isoforms
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(AT1A and ATIB), at least in murine species [3—7]. Important
differences were observed at the level of their tissue distribution
and regulation [8—11]. Although the function of the AT2 receptor
type remains unknown, binding studies have shown a well defined
distribution of the AT2 receptor type in the adult rat uterus, ovary,
adrenal gland, kidney, brain [1, 2], as well as in the rat fetus at the
end of gestation [12—14].
The recent cloning of the AT2 receptor eDNA in rat [15, 16] or
in mouse [17] showed that, like the AT1 receptor, it belongs to the
family of the seven transmembrane domain receptors. These two
receptor types are 34% identical in their amino acid sequence.
The signal transduction mechanism(s) of the AT2 receptor is
debated [1, 2, 15] as well as its functions, even though its
expression during fetal development and its disappearance after
birth suggest a role in organogenesis.
As Ang II antagonists will be used clinically to control blood
pressure, it is crucial to identity the tissues that express the Ang II
receptor genes and determine whether or not they are involved in
cardiovascular homeostasis. Expression of a functional receptor at
the cell surface can be affected at the level of transcription of the
mRNA, stability of the message, translation into protein, trans-
port to the cell surface and enzymatic modifications affecting
activity or binding. Hence it is of particular interest to characterize
the spatiotemporal pattern of expression of the AT2 receptor
mRNA to study the expression of this receptor gene. The present
in situ hybridization study of AT2 receptor mRNA expression
during development could be useful to validate and complete
already existing data obtained by in situ autoradiographic binding
studies.
Using the published sequence of the AT2 receptor eDNA [15,
16] a polymerase chain reaction (PCR) product corresponding to
the first 160 amino acid sequence of the rat AT2 receptor was
synthesized by reverse transcriptase (RT) PCR amplification of
rat adrenal total RNA. This new method [18] involves a reverse
transcription and PCR amplification, using primers containing
specific sequences of the AT2 receptor and additional sequences
of the T7 and 5P6 RNA polymerase promoters. Sense and
antisense cRNA probes were generated in vitro from this ampli-
con and used for in situ hybridization to establish the spatio-
temporal expression of the AT2 receptor mRNA in the fetal and
newborn rat, with particular emphasis on the kidney and adrenal
gland. This distribution was compared to that of AT1A receptor
mRNA.
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Method
Primer design
DNA sequences were chosen to amplify a 500 bp fragment. The
primers, selected in the rat AT2 eDNA sequence [15, 16], dis-
played no homology with the rat AT1Aor ATIB cDNA sequences
[3, 4]. Sequences for T7 or SP6 promoters along with additional
sequences required for optimal transcription efficiency for each
polymerase [19] were added respectively to the sense and anti-
sense primers. The primers were synthesized using a PCR-mate
391 device (Applied Biosystems). The sense primer contained the
T7 promoter sequence and 23 bp of the AT2 receptor sequence
(5'-TAA TAC GAC TCA CTA TAG GGG ATC ATG AAG
GAC AAC TIC AGT TTr GC-3'). The reverse primer contained
the SP6 promoter sequence and 22 bp of the AT2 receptor
sequence (5'-AAT TAG GTG ACA CTA TAG GAT CCC CAA
GGG GAA CTA CAT AAG ATG C-3'). The pair of AT2
receptor primers included nucleotides 1-23 and 478-499 of the
AT2 receptor cDNA and thus amplified 499 bp in the 5' coding
region.
RT-PCR amplification
Moloney murine leukemia virus reverse transcriptase (200 U,
BRL, Bethesda, MD, USA) was used to synthesize (90 mm, 37°C)
a single stranded cDNA from 4 ig rat adrenal total RNA in the
presence of 0.5 LM of the reverse primer in 20 d of 50 mM
Tris-HCI buffer (pH 8.3), 75 mM KC1, 3 mr't MgC12, 2.5 mM dNTP,
10 mM dithiothreitol and 40 units of RNase inhibitor (Boehringer,
Mannheim, Germany). Double stranded cDNAs were synthesized
and amplified using 2.5 units of Taq polym erase (Boehringer) and
80 n sense and antisense primers in 100 jLl of 20 mvt Tris-HC1
buffer (pH 8.3), 65 mvi KCI, 2.5 mivi MgCl2, 0.5 miu dNTP, 2 mM
dithiothreitol and 0.01% gelatin for 35 cycles at 92, 54 and 72°C
for 1.00, 1.00 and 1.30 minutes, respectively. PCR products were
electrophoresed in 1.5% agarose gels and visualized by ethidium
bromide staining. Restriction enzyme analysis of PCR products
was performed on 20 d of the PCR reaction medium, which was
diluted twofold in autoclaved H20 and incubated for 90 minutes
at 37°C in presence of KpnI (10 units) or Apal (10 units).
Digestion analysis was resolved by separating the different frag-
ments on 1.5% agarose gel for visual verification.
Sequencing of PCR products
PCR products were gel purified using the Qiaex gel extraction
kit (Qiagen, Invitrogen, Oxon, UK) and submitted after denatur-
ation to direct sequencing on both strands by the dideoxynucle-
otide chain termination method using a Sequenase kit (United
States Biochemical Corp., Cleveland, OH, USA). The denatur-
ation step of the template DNA was performed by heating for five
minutes at 94°C in the presence of 10 pmol of sequencing primer
and DMSO, then by chilling in ethanol/dry ice. Sequencing
reactions were stopped by the addition of formamide, run on a 6%
denaturing polyacrylamide gel and visualized by autoradiography.
Labeling of complementary RNA (cRNA) probes
cRNAs were transcribed by RNA polymerases (Promega Bio-
tech, Madison, Wis, USA) in the presence of 35S-UTP (Amer-
sham, Les Ulis, France), starting from the SP6 or T7 promoter
sequence, using 7 pA of the PCR reaction product. The labeled
transcription products were verified on a 1.2% agarose gel. The
ATIA eDNA was prepared following a previously described
procedure [10], linearized by Asel and transcribed by T3 RNA
polymerase to synthesize the ATIA antisense cRNA probe, and
likewise the AT1A sense probe was produced after linearization by
BamHI and transcription by T7 RNA polymerase.
In situ hybridization
Timed pregnant rats (Sprague Dawley, purchased from Iffa-
Credo, Les Oncins, France) were sacrificed by lethal chloroform
anesthesia at 13 (E13), 15 (E15), 17 (E17) and 19 (E19) days of
gestation, and the fetus, either together with the placenta (E13) or
alone, were removed from the mother and fixed by immersion in
4% paraformaldehyde. Newborn rats at day 0 (DO; 2 hr post-
partum), 1 (DI), 3 (D3), and 10 (D1O) were sacrificed by
decapitation under chloroform anesthesia and the organs taken
out to be fixed. The hybridization procedure (tissue preparation,
paraffin embedding, prehybridization, hybridization and post-
hybridization washes) was as previously described [10, 20]. The
hybridization signal was observed macroscopically after autora-
diography of the sections on J3-Max (Amersham) or X-OMAT
AR (Kodak, Rochester, NY, USA) films for 3 to 5 days. The slides
were dipped in liquid emulsion (NTB2, International Biotechnol-
ogies, mc, New Haven, CT, USA), and after two weeks of
exposure, they were photographically processed and counter-
stained with toluidine blue.
Results
To prepare a specific rat AT2 riboprobe, total RNA from rat
adrenals and an antisense primer including both the sequences of
the AT2 receptor and the SP6 RNA polymerase promoter were
used as templates. Single cDNA strands were obtained by reverse
transcription. Double cDNA strands were synthesized by PCR
amplification between this reverse primer and a sense primer
including both the sequences of the AT2 receptor and the T7
RNA polymerase promoter (Fig. 1). These conditions produced
only one PCR product with the expected size of 544 bp (499 bp of
the AT2 receptor and 45 bp of the SP6 or T7 promoter sequenc-
es). The digestion of this product by KpnI or Apal generates
fragments of either 453 and 94 bp or 299 and 248 bp, respectively
(Fig. 2), in agreement with the restriction map of the AT2
receptor cDNA [15, 16]. Furthermore, the sequence analysis of
the PCR product by directly sequencing both strands without
subcloning allowed the identification of 200 out of 499 bp,
corresponding to the nucleotides 65 to 165 and 305 to 405 of the
rat AT2 receptor sequence [15]. Taken together, these results
demonstrated that the synthesized PCR product corresponds to
the 1 to 499 bp of the rat AT2 receptor cDNA.
Direct transcription of this PCR product without purification
(considering that all the RT-PCR amplification procedure was
performed in RNase free solutions) produced 35S labeled sense
and antisense RNA probes (specific activity 1.5 x 108 cpm/jg) by
the use of respective T7 and SP6 RNA polymerase promoters.
Analysis of the transcription products by agarose gel electro-
phoresis, followed by autoradiography, showed the presence of a
single band of the expected size (547 bp) for the sense as well as
for the antisense riboprobes, demonstrating in each case the
synthesis of full length cRNA transcripts (Fig. 3). These cRNA
probes were subsequently used for mapping the AT2 receptor
mRNA by in situ hybridization.
Tissues were hybridized with the AT1A and AT2 sense and
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Fig. I. Schematic representation of the strate& used to generate single
stranded RNA probes. Total RNAfrom rat adrenals was used as a template
to synthesize a single strand eDNA in the presence of a specific reverse
primer including the sequence of the SP6 promoter and that of the AT2
receptor. Double stranded eDNAs were obtained after PCR amplification
between this reverse primer and a sense primer including the sequence of
the T7 promoter and that of the Al'2 receptor. The PCR product was then
directly used for synthesizing cRNA probes in a transcription reaction with
either T7 or SPb RNA polymerase in the presence of 35S-UTP.
antisense probes. The overall distribution of ATIA and AT2
receptor mRNAs shown by in situ hybridization in the rat fetus is
different for each receptor type (Fig. 4). AT1 A mRNA was
detected at all stages studied, either as a weak and diffuse labeling
at E13, or as a distinct signal located in definite organs or parts of
organs at later stages (E15 to E19): kidney, adrenal cortex, liver,
lung, heart, aorta, pituitary gland and brain. A diffuse but strong
labeling was also observed in the para-axial mesenehyme of the
back at E15, of the tail at EU, and in the epidermis at E19.
reverse primer
AT2 SP6 I 5'/ 0-5 Kb
I SF6] Fig. 3. Agarose gel analysis of 11S-labeled transcripts: ATJA antisense (lane
1), and AT2 antisense (lane 2) and sense (lane 3) transcription products
shows hands at the expected sizes of ao to 0.7kb (AT/A) and 0.5 kb (AT2).
Absence of labeling was seen at E17 with the ATIA sense probe.
In contrast, AT2 receptor mRNA was first detected at E13 as a
series of small paired spots symmetrically located on each side
along the embryo axis (not shown). As early as E15 the differen-
tiating kidney displayed a hybridization signal in the cortex and/or
the capsule (Fig 4). In the adjacent adrenal gland the outer layer
of the cortex was strongly labeled. At E15, a signal was observed
in the para-axial mesenehyme in the lower part of the body, and
a very intense signal in the tongue and the pharyngeal region. In
the fetus at E17, the distribution and intensity of labeling did not
change significantly as compared to E15. The labeling of the
tongue remained very strong and expanded as the tongue grew. In
addition, the skin was distinctly positive at some regions of the
back. At 19 days of gestation, all organs above described as
labeled, remained positive for the AT2 probe. The strong signal in
the adrenal gland appeared to be restricted to the capsule and the
zona glomerulosa of the adrenal cortex, and in the medulla,
whereas the adjacent kidney displayed a weaker labeling, in outer
medulla and cortex. In the deeper layers of the skin, the labeling
was generalized over the whole body. The tissue surrounding the
—463 vertebrae and ribs showeda clear signal, as did the outline of the
stomach, the trachea, the bronchi and the aorta. In the head, the
—299 tongue, the whole phatyngeal area, and particularly the epiglottis,
displayed the strongest signal together with the snout and nasal
—248 cavity. The skin and the inner lining of the bueeal cavity were also
labeled. As a control, no significant signal was observed at any
developmental stage with the AT2 sense probe.
For technical reasons, it was impossible to work with the whole
body of newborn rats, even one hour after birth. The size of the
newborn and the low permeability of keratinized skin to the
various solutions (fixatives and dehydration solvents) precluded
the use of whole body sections. Organs were therefore dissected
and individually processed.
After birth (Figs. 5 and 6), ATIA receptor mRNA was detected
in the kidney, heart, thymus, adrenal gland (zona glomerulosa and
medulla), pituitary gland and liver. AT2 receptor mRNA re-
mained detectable in the adrenal gland after birth and until adult
life. In the newborn at D3 and in the adult adrenal gland,
microscopic images revealed the presence of AT2 mRNA only in
the zona glomerulosa, and no labeling was seen in the zona
faseieulata and zona retieularis (Fig. 6 A, C). In the medulla the
AT2
undigested Apa I Kpnl
544 bp—
Fig. 2. Gel electrophoresis of PCR products. PCR products obtained from
rat adrenal total RNA, as described in Methods, were electrophoresed on
1.5% agarose gel either directly (lane 1) or after digestion by Apal (lane
2) or KpnI (lane 3). The sizes of the fragments are indicated on the right
and left of the figure.
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Fig. 4. Film autoradiography after in situ hybridization with A TIA receptor antisense probe (al to ci), AT2 receptor antisense probe (a2 to e2) and AT2
receptor sense probe (a3 to c3) and the ATIA sense probe d3, in the rat fetus at 15 (al, a2, a3), 17 (bi, b2, b3 and d3), and 19 (ci, c2, c3, d2, ci and e2)
days of gestation. All sections are parasagittal. To: tongue; Ad: adrenal gland; Ki: kidney; Br: bronchus; St: stomach; Pi: pituitary gland. Magnification
x2.
Fig. 5. Film autoradiography after in situ hybridization with ATIA receptor antisense probe (al to el), and AT2 receptor antisense probe (a2 to e2). al and
a2: frontal sections of the head of a newborn rat at DO; bi and b2: skin of newborn rat at DO; ci and c2: heart and thymus at Di; dl and d2: kidney
and adrenal gland at D3; ci and e2: kidney at DlO. To: tongue; Th: thymus; Br: bronchus; Md: adrenal medulla. Magnification X2.
labeling was heterogeneous as if only some cords of cells were
positive. In the kidney, the labeling was clearly visible although
weaker than in the adrenal gland, and it appeared to be located
mainly in the outer cortex and medulla. The signal in the kidney
decreased between D3 and D1O (Fig. 5). The heart displayed a
weak labeling comparable to the background obtained with the
sense probe. In the head, at DO and Dl the same structures as in
the 19-day-old fetus remained positive: tongue, walls of the buccal
cavity and lateral jaw muscles. In addition, the lining of the orbital
cavity and a subepidermal layer of the skull were also labeled. The
tongue remained labeled at Dl but was not examined at later
stages. The labeling in the skin at DO and Dl was much weaker
than in the fetus.
Discussion
The simple method initially described by Bean, Simons and
HOkfelt [18] was utilized, after slight modification, to generate
AT2 receptor single stranded cRNA probes that were used to
establish the distribution of the AT2 receptor mRNA in the rat
fetus and the newborn rat.
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Fig. 6. AT2 receptor mRNA expression in the adrenal gland after in situ hybridization, a. Emulsion autoradiographic image of the adrenal cortex at D3.
b. Film autoradiography of the adult adrenal gland. c. Emulsion autoradiographic image of the adult adrenal cortex. Ca: capsule; Zg: zona glomerulosa.
Exposure time: a and c 2 weeks. Magnification: a and c x 400; b X 4.
The AT2 receptor mRNA was detected in known target organs
for Ang II (kidney, adrenal gland, large blood vessels) and also in
various tissues where no hormonal effect of this peptide has been
described, particularly in differentiated and undifferentiated mes-
enchymes. AT2 receptor mRNA was detectable at the earliest
stage studied, 13 days of gestation. The AT1A receptor mRNA
was also detected in targets organs for Ang 11, some of which are
the same as for AT2 (kidney, adrenal gland, large blood vessels)
and others which are unique to ATIA (liver, lung, pituitary gland).
Similarly, some of the mesenchymes which express AT1A receptor
mRNA also express AT2 (perichondrion), but others express only
AT2 (tongue, bronchi). The distribution of AT1 A and AT2 recep-
tor mRNAs appears to be specific for each of the receptor types,
an observation which favors a selective role for AT1 and AT2
receptors.
The distribution of the AT1 and AT2 receptor mRNAs in the
fetus and the newborn generally coincides with the distribution of
Ang II binding sites as shown by in situ autoradiography [12] and
more specifically with AT2 binding studies using selective ligands
[13, 14]. These in situ autoradiographic studies have revealed the
presence of AT2 receptors in the rat fetus, in the same tissues and
organs that are shown in the present study to express AT2
receptor mRNA, with the notable exception of the fetal and
newborn zona glomerulosa. Indeed, both in situ binding studies
which selectively detected AT2 receptor [13, 14] did not mention
the presence of binding sites in this tissue, which is one of those
displaying the strongest hybridization signal for AT2. The discor-
dance between the in situ hybridization and in situ autoradio-
graphic binding studies could be related to differences in the
turnover rate of the mRNA and the protein.
Another interesting observation is the differential expression of
the AT2 receptor during development between the kidney and the
adrenal gland. While a high level of AT2 receptor mRNA
expression persists in the adrenal (zona glomerulosa and medul-
la), the labeling tends to decrease between D3 and D10 in the
kidney. There are conflicting results concerning the presence of
AT2 binding sites, detected by autoradiography, in the kidneys.
While Ciuffo et al [21] reported AT2 binding sites in immature
glomeruli of fetal and newborn rat kidney, Grady et al [13] and
Tsutsumi et al [14] did not mention AT2 binding sites in the
kidney in their study using the rat fetus. Other studies in the adult
rat failed to detect significant levels of AT2 receptor binding in the
kidney [22, 23]. The present study shows that the AT2 receptor is
expressed in the kidney, until at least 10 days after birth with an
apparently different distribution from that of AT1, as revealed by
in situ hybridization [24—26]. The identification of the cells in
which AT2 receptor mRNA is expressed will help to understand
the potential roles of Ang II via this receptor type in the kidney.
It is generally agreed that the AT2 receptor is mainly present
during fetal life and disappears at birth [13, 141. Thus, this
receptor type could be involved in an Ang II induced differenti-
ation process during development. The present study supports
this view by showing the spatiotemporal regulation of the AT2
receptor mRNA expression in the rat fetus, particularly in various
mesenchymes. It should be noted, however, that the ATIA recep-
tor is also expressed during fetal life, with a different and wider
pattern of distribution, and could therefore also play a role during
development. Even though the AT2 receptor may not mediate the
known physiological functions of Ang II in the kidney or the
adrenal gland, since no definitive effect can be ascribed to the
binding of Ang II to this receptor type, the AT2 receptor may be
involved in the organogenesis of these organs as well as in the
differentiation process of various mesenchymes in which the AT2
receptor mRNA is detected. Microscopical and physiological
studies will be necessary to identify and characterize the target
cells for Ang II and to clarify the exact role(s) of AT2 as well as
AT1A receptors in the development.
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